Black Diamond Therapeutics Inc.
| NASDAQ: BDTX | Healthcare / Biotechnology / USA |
| 24.34 | -1.52 | -5.88% | Vol 136.17K | 1Y Perf -17.92% |
| Apr 19th, 2021 14:39 DELAYED |
| BID | 24.31 | ASK | 24.42 | ||
| Open | 25.83 | Previous Close | 25.86 | ||
| Pre-Market | - | After-Market | - | ||
| - -% | - - |
| Target Price | 51.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 108.42 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 879.60M | Earnings Rating | — | |
| Price Range Ratio 52W % | 13.09 | Earnings Date | 11th May 2021 |
Today's Price Range 24.0325.92 | 52W Range 21.0446.25 |
Summary:
Neutral
| Technical Indicators: | Buy |
| Moving Averages: | Neutral |
| Performance | |||
|---|---|---|---|
| 1 Week | 4.99% | ||
| 1 Month | 0.04% | ||
| 3 Months | -4.01% | ||
| 6 Months | -23.26% | ||
| 1 Year | -17.92% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | -51.61 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -27.57 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -27.44 | |||
Return on invested Capital Q | -7.32 | |||
Return on invested Capital Y | -51.28 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -12.10 | ||||
| 2.92 | ||||
| - | ||||
| - | ||||
| -21.90 | ||||
| -1.58 | ||||
| 2.92 | ||||
| 8.52 | ||||
| 591.33M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 22.20 | ||||
| 22.50 | ||||
| 0.02 | ||||
| 0.03 | ||||
| -67 253.00 | ||||
| Leverage Ratio | 1.00 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2020 | -0.63 | -0.63 | 0.00 |
| Q03 2020 | -0.53 | -0.50 | 5.66 |
| Q02 2020 | -0.43 | -0.41 | 4.65 |
| Q01 2020 | -0.47 | -0.51 | -8.51 |
| Q04 2019 | -1.37 | -4.63 | -237.96 |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 11th May 2021 |
| Estimated EPS Next Report | -0.67 |
| Estimates Count | 5 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 136.17K |
| Shares Outstanding | 36.14M |
| Trades Count | 2.39K |
| Dollar Volume | 10.86M |
| Avg. Volume | 442.58K |
| Avg. Weekly Volume | 315.40K |
| Avg. Monthly Volume | 391.71K |
| Avg. Quarterly Volume | 417.08K |
Black Diamond Therapeutics Inc. (NASDAQ: BDTX) stock closed at 25.86 per share at the end of the most recent trading day (a 2.54% change compared to the prior day closing price) with a volume of 206.34K shares and market capitalization of 879.60M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 58 people. Black Diamond Therapeutics Inc. CEO is David M. Epstein.
The one-year performance of Black Diamond Therapeutics Inc. stock is -17.92%, while year-to-date (YTD) performance is -19.31%. BDTX stock has a five-year performance of %. Its 52-week range is between 21.04 and 46.25, which gives BDTX stock a 52-week price range ratio of 13.09%
Black Diamond Therapeutics Inc. currently has a PE ratio of -12.10, a price-to-book (PB) ratio of 2.92, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -27.57%, a ROC of -27.44% and a ROE of -51.61%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Black Diamond Therapeutics Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.67 for the next earnings report. Black Diamond Therapeutics Inc.’s next earnings report date is 11th May 2021.
The consensus rating of Wall Street analysts for Black Diamond Therapeutics Inc. is Strong Buy (1), with a target price of $51, which is +108.42% compared to the current price. The earnings rating for Black Diamond Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Black Diamond Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Black Diamond Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 10.17, ATR14 : 1.79, CCI20 : 83.59, Chaikin Money Flow : 0.07, MACD : -0.74, Money Flow Index : 51.86, ROC : 14.58, RSI : 55.14, STOCH (14,3) : 91.58, STOCH RSI : 1.00, UO : 57.91, Williams %R : -8.42), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Black Diamond Therapeutics Inc. in the last 12-months were:
Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform namely, Mutation-Allostery-Pharmacology which is targeting mutations in cancer.
CEO: David M. Epstein
Telephone: +1 617 252-0848
Address: 139 Main Street, Cambridge 02142, MA, US
Number of employees: 58
